[Dangerous thrombocytopenia in thrombolytic therapy of venous thrombosis of the leg].
Two days after 5 days heparin treatment of a superficial thrombophlebitis a 45 year old woman was admitted to hospital with an extended phlebothrombosis of a leg. Before starting thrombolytic treatment a bolus of 5000 U heparin followed by 1000 U/h was administered. During thrombolytic treatment with ultrahigh streptokinase the platelet count dropped from 172,000/microliter to 73,000 and 29,000/microliter. Thrombocytopenia was considered not to be a complication of thrombolytic therapy but by demonstrating heparin induced platelet antibodies to be due to a heparin-associated thrombocytopenia type II (HAT Type II).
Fischer
M
M
Medizinische Klinik des Kreiskrankenhauses Neustadt am Rübenberge.
Tempel
J
J
Schenker
G
G
D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D013924:Thrombophlebitis / Q000188:drug therapy*
D006493:Heparin; D013300:Streptokinase